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Abstract
This critical review evolved from a SNO Special Workshop on Nanoceria panel presentation
addressing the toxicological risks of nanoceria: accumulation, target organs, and issues of
clearance; how exposure dose/concentration, exposure route, and experimental preparation/model
influence the different reported effects of nanoceria; and how can safer by design concepts be
applied to nanoceria? It focuses on the most relevant routes of human nanoceria exposure and
uptake, disposition, persistence, and resultant adverse effects. The pulmonary, oral, dermal, and
topical ocular exposure routes are addressed as well as the intravenous route, as the latter provides
a reference for the pharmacokinetic fate of nanoceria once introduced into blood. Nanoceria
reaching the blood is primarily distributed to mononuclear phagocytic system organs. Available
data suggest nanoceria’s distribution is not greatly affected by dose, shape, or dosing schedule.
Significant attention has been paid to the inhalation exposure route. Nanoceria distribution from
the lung to the rest of the body is less than 1% of the deposited dose, and from the gastrointestinal
tract even less. Intracellular nanoceria and organ burdens persist for at least months, suggesting
very slow clearance rates. The acute toxicity of nanoceria is very low. However, large/
accumulated doses produce granuloma in the lung and liver, and fibrosis in the lung. Toxicity,
including genotoxicity, increases with exposure time; the effects disappear slowly, possibly due to
nanoceria’s biopersistence. Nanoceria may exert toxicity through oxidative stress. Adverse effects
seen at sites distal to exposure may be due to nanoceria translocation or released biomolecules. An
example is elevated oxidative stress indicators in the brain, in the absence of appreciable brain
nanoceria. Nanoceria may change its nature in biological environments and cause changes in
biological molecules. Increased toxicity has been related to greater surface Ce3+, which becomes
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more relevant as particle size decreases and the ratio of surface area to volume increases. Given its
biopersistence and resulting increased toxicity with time, there is a risk that long-term exposure to
low nanoceria levels may eventually lead to adverse health effects. This critical review provides
recommendations for research to resolve some of the many unknowns of nanoceria’s fate and
adverse effects.
Introduction
The availability of cerium dioxide (a.k.a.: CeO2, ceria, cerium oxide) as one of the most
abundant rare earth oxides has prompted research on the synthesis and development of
functional ceria nanoparticles. As a result, nanoceria is increasingly used in a variety of
industrial and commercial applications, including catalysis 1, 2, e.g., as a diesel fuel additive
to increase fuel combustion efficiency and decrease soot emissions 3, 4; in chemical
mechanical planarization/polishing 5; UV-shielding 6; in semiconductors; in toner
formulations 7; and as an additive in various nanocomposites, as reviewed 8. The inevitable
increase in consumer and occupational exposures raises the need for a comprehensive
toxicological characterization of nanoceria 9. Many companies and organizations have
already identified nanoceria as a high priority material for toxicological evaluations 10, 11.
This critical review focuses on the potential routes of human exposure to nanoceria and its
extent of uptake from those routes, and its distribution, retention, and resultant effects. The
mechanisms of its adverse effects described to date are primarily gleaned from in vitro
studies. Each major section is concluded by what we know and knowledge gaps. Research
recommendations, that will hopefully advance the understanding of nanoceria risk, are
offered in the conclusion of this critical review.
In the context of unintended nanoceria exposure, pulmonary exposure has received the most
attention. Other exposure routes are discussed, including intravenous, dermal, oral, and
ocular.
Systemic nanoceria exposure
The pharmacokinetics of systemically-administered nanoceria
The intravenous (IV) route provides pharmacokinetic and pharmacodynamic insight into the
fate of nanoceria that is introduced into blood, or that is in blood after distribution from the
site of uptake. Introduction into blood provides 100% bioavailability, against which uptake
from other sites can be compared. Intravenous administration is also a potential route of
administration for the use of nanoceria as a therapeutic agent, for described conditions 12,
and those identified in the future.
The distribution and short term persistence of a commercial platelet nanoceria, that had a
median primary particle diameter of 31 nm (based on size), was assessed after IV
administration of 50, 250, and 750 mg/kg bw to rats. It was infused at a rate of 100 mg/kg/
h 13 as a 5% dispersion in water with concurrent IV infusion in a second cannula of 1.8%
sodium chloride. Blood cerium concentration initially decreased with a t½ of 7.5 min. Blood
cerium concentration increased slightly from 120 to 240 min after completion of the
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nanoceria infusion, an unexpected trend. Cerium concentrations in the spleen, liver, blood,
and brain were higher 20 h than 1 h post-infusion, suggesting some nanoceria was in other
compartments at the earlier time point and translocated back into blood and to the 3
measured organs at 20 h. This observation was investigated with intra-arterial infusion at 20
ml/min of up to 500 µg/ml of a 5 nm ceria for 120 seconds, which demonstrated nanoceria
association with the brain microvasculature luminal wall 14. The capillary depletion method
showed essentially all of the nanoceria associated with the capillary fraction, and electron
microscopy showed it located on the endothelial cell luminal surface 14. Given the uptake t½
of nanoparticles by several cell types was 1 to > 2 h 15, nanoceria associated with the
luminal surface of endothelial cells 120 seconds after its intra-carotid artery infusion might
eventually be taken up by cells. However, light and electron microscopy have not revealed
any appreciable nanoceria in brain parenchyma (neurons or astrocytes), including the
median eminence, a brain region lacking a blood-brain barrier (BBB), after IV
administration of 5, 15, or 30 nm citrate-coated polyhedral or cubic nanoceria 13, 16–18.
Nanoceria adsorption to the luminal wall of vascular endothelial cells may be the site of
nanoceria distribution after leaving circulating blood, from which it re-entered circulating
blood and distributed to peripheral organs.
When terminated 1 or 20 h after completion of 50, 250, and 750 mg/kg of the IV infusion of
the 30 nm platelet nanoceria, a dose-dependent increase of cerium in the spleen, liver, blood,
and brain was seen, indicating the lack of organ saturation of nanoceria accumulation within
this short time frame. Cerium concentrations were higher in the spleen than liver. The
percentages of the injected dose in the liver and spleen are shown in Figure 1. Less was in
the blood (0.2 to 4%) and much less in the brain (< 0.1%). This distribution is similar to that
reported by others (Figure 1) and described below 19. Twenty h after its infusion,
intracellular nanoceria agglomerations were seen in macrophage-rich spleen red pulp,
Kupffer cells, and hepatocytes. Nanoceria accumulations were seen in the afferent arterioles
leading into the glomeruli. Much of the cerium in the brain was probably nanoceria in
circulating blood within the brain’s vasculature, and perhaps associated with the endothelial
cells lining the brain’s blood vessels as seen after intra-carotid nanoceria infusion, noted
above, and as 100 to 200 nm irregular granules within plasmoid material in blood vessels in
the tail after IV tail vein nanoceria injection to the mouse 14, 20. The very few nanoceria
particles seen in brain parenchyma might be an artifact of tissue preparation (sectioning) for
electron microscopic visualization. In summary, this study showed rapid clearance from
blood circulation of most of the nanoceria into mononuclear phagocyte system (MPS)
organs and very little to no nanoceria BBB penetration into brain parenchyma.
The biodistribution of a smaller (3 to 5 nm primary particle size, 15 to 20 nm
agglomerate 21) fluorescent-tagged crystalline ceria was determined in CD-1 mice 7 days
after 2 or 5 weekly IV 0.5 mg/kg injections 19. The spleen had the highest cerium
concentration, followed closely by the liver, consistent with the study presented above. More
of the dose was in the liver and spleen (Figure 1) than the lung (0.15%) or kidney (0.008%).
None was detectible in the brain. Organ cerium concentrations were about 3 times higher in
the mice that received 5 vs. 2 injections. Cerium clearance into urine was not detectable. The
results demonstrate that this nanoceria dose did not saturate the organs and that very little
was cleared during the 35 day post exposure period. Assuming the 3-aminopropylsilyl-
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anchored N-succinimidyl 4-[18F]fluorobenzoate coated nanoceria retained the positive
surface charge (+18.5 mV) that it had before N-succinimidyl 4-[18F]fluorobenzoate coating,
this is the only positively-charged nanoceria for which biodistribution results have been
reported after its IV administration. The results shown in Figure 1 do not suggest it behaved
significantly differently from the other nanoceria that had a negative surface charge.
Distribution and retention of a ceria nanorod (diameter and length averages of 10 and 264
nm) was generally not different from that seen after IV infusion of a 5 nm polyhedral or a 30
nm cubic ceria 25. Available results do not suggest nanoceria shape has a profound influence
on cerium distribution.
Several studies report the use of functionalized nanoceria. Distribution of a N-succinimidyl
4-[18F]fluorobenzoate covalently anchored 3-(aminopropyl)triethoxysilane functionalized ~
5 nm ceria in rats detected by positron emission tomography showed ~ 6, 2, 2, and 1% of the
dose per gram liver, spleen, lung, and kidney, respectively 23. Figure 1 shows the percentage
of the dose of this small nanoceria in the liver and spleen was similar to results obtained
with other nanoceria. A 2.9 nm citrate/EDTA-coated nanoceria injected IV to mice (20
mg/kg) in a citrate buffer produced a similar pattern; highest levels in the liver and spleen
(Figure 1), lower in the kidney, and lowest in the brain 24. Levels decreased over 5 months
(Figure 1). The rats were vascularly perfused prior to organ removal so the brain cerium
levels should not reflect nanoceria in blood within the brain. After repeated dosing, cerium
levels in the cerebellum were higher than in the combined brain and spinal cord. Brain
nanoceria was much higher in mice with experimental autoimmune encephalomyelitis,
perhaps due to the loss of BBB integrity in this pathology 24. TEM showed intracellular
nanoceria in myelinated processes, axons, dendrites, and mitochondria of the cerebellum.
This is the only report with good evidence of nanoceria distribution across the BBB into
brain parenchyma.
To determine if nanoceria size has a significant effect on its pharmacokinetics after IV
administration, citrate-coated (ζ potential −32 to −57 mV), ~ 5, 15, 30, and 55 nm cubic/
polyhedral nanoceria and a mixture of 30 nm cubic and rod nanoceria were prepared and
extensively characterized 22. Their pharmacokinetics after a 1 h IV infusion of a single dose
(70 or 85 mg/kg) to rats was determined by repeated blood sampling. Partitioning between
blood components, compared to the cerium ion, was also determined 26. The percentage of
the nanoceria dose remaining in circulating blood 10 minutes after completion of its iv
infusion was < 2% for the 15, 30, and 55 nm ceria, indicating very rapid translocation, as
seen with the 30 nm commercial nanoceria 13. In contrast, 10 minutes after the 1 h infusion
of 5 nm ceria ~ 35% was still circulating in the blood, perhaps because it was too small to be
readily recognized by macrophages and was able to avoid opsonin adsorption or blood cell
attachment 12. This was cleared with initial and beta t½s of 0.4 and 124 h. Similarly, a
citrate-EDTA-coated 2.9 nm ceria was cleared from blood with a plasma t½ of 3.7 h 24. An
increase of ceria in blood was seen 2 to 4 h after infusion of the 15 and 30, but not 5 or 55
nm, ceria or the cerium ion. This is not typical following IV administration, and suggests
nanoceria re-entry into circulating blood, an observation seen with the commercial 30 nm
ceria, above 13, or solubilization of nanoceria releasing cerium ions, although this is much
less likely within 2 to 4 h.
Yokel et al. Page 4
Environ Sci Nano. Author manuscript; available in PMC 2015 October 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
To ascertain the distribution of these 4 nanoceria within blood after their IV administration,
plasma was separated from blood cells by allowing the blood to clot and separating the clot
from plasma without using centrifugation that would bring down the nanoceria. This
separation showed an increase of nanoceria associated with the clot over 4 h of 15 and 30,
but not 5 or 55 nm, ceria. This could be due to protein coating, given this is a very rapid
process and known to occur with nanoceria 12, 27. Such coating could explain the release of
nanoceria from vascular endothelial cell wall adsorption and its re-entry into circulating
blood. Nanoceria agglomerations were seen in blood after 1 h incubation of 30 nm ceria 13
and 5 nm ceria 16. Some of the agglomerates appeared to be adherent to erythrocytes 16,
perhaps a process similar to the adsorption of 7 nm ceria agglomerates to the external cell
membrane of fibroblasts 28. Nanoceria may agglomerate or be protein coated quickly once it
contacts blood, affecting the ability of macrophages to recognize them as foreign particles to
be cleared into MPS organs.
Classical pharmacokinetic analysis, based on blood levels of 5, 15, 30, and 55 nm ceria and
a mixture of 30 nm cubic and rod nanoceria after their iv administration, did not describe
their fate well 26. This is consistent with observations that the fate of insoluble
nanomaterials is different than that of small molecules 29–31. Differences include
agglomeration that probably occurs in circulating blood and is seen in MPS organs where
they accumulate (below), rapid clearance from circulation presumably by macrophages
rather than blood flow (yielding short blood t½s that do not reflect the whole organism t½),
some re-entry into circulating blood resulting in increased concentration hours after IV
dosing, movement across cell membranes that is not diffusion-based or as substrates for
active transporters, and distribution into MPS sites in which they persist with little
elimination from the organism which is inconsistent with partition coefficient distribution
between blood and tissues.
To determine the fate of the 5, 15, 30, and 55 nm ceria, liver, spleen, blood, and brain were
collected up to 30 days after their single IV infusion over 1 h to rats 22. Blood 5 and 15 nm
ceria decreased from 1 to 30 days whereas the 30 nm ceria was higher 20 h, compared to 1
h, after administration, again suggesting mobilization from a site outside of circulating
blood. Brain cerium decreased over time, probably reflecting the clearance of ceria from
blood, and perhaps mobilization of vascular endothelial cell wall-adsorbed nanoceria. Liver
and spleen cerium did not decrease from 1 h to 30 days, and in some cases significantly
increased (Figure 1). These results are consistent with some redistribution within, and the
lack of significant elimination from, the rat, as observed up to 14 days by us, noted below 18
and 42 days by others 19.
To extend the duration of observation and much more extensively characterize nanoceria’s
fate, rats were evaluated 1, 7, 30, or 90 days after a single 85 mg/kg IV infusion of 30 nm
ceria 18. Total urine and feces collection for 14 days showed 0.01 and 0.4% of the dose
eliminated in these excretia, respectively. Similarly, some cerium was eliminated in feces,
but none was detected in urine, after IV administration of 0.5 mg/kg of a 3 to 5 nm ceria 19.
Cerium concentration in 16 organs showed spleen, liver, bone marrow, and skeletal system
with 21 to 37, 5 to 15, 9 to 27, and 2 to 8% of the dose, respectively 18. The percentage of
the dose in liver and spleen is shown in Figure 1, compared to other studies. Distribution
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among these 16 organs was consistent with prior findings with 30 and 3 to 5 nm primary
particle size nanoceria (above) and its distribution in organs distal to the site of
administration when given orally or into the lungs (below). Blood, cerebrospinal fluid, and
most organs showed an increase of cerium 90 days after nanoceria administration, whereas
this was not seen in the liver (Figure 1), bone marrow, or skeletal muscle, suggesting some
redistribution from 30 to 90 days after nanoceria infusion. Light and electron microscopic
assessment of MPS organs of these animals showed large (up to 5 µm) nanoceria aggregates
predominantly in the phagolysosomes of Kupffer cells, but also in hepatocytes, as early as 1
h after its administration. The nanoceria aggregates persisted to 90 days, consistent with the
lack of appreciable change in cerium in the liver. Nanoceria was not seen in bile canaliculi,
consistent with the lack of significant fecal excretion.
In summary, the above studies generally show similar nanoceria distribution after IV
administration, characterized by rapid translocation from the blood into the MPS with spleen
having with the highest concentration and liver the greatest burden. The 2.9 and 5 nm ceria
were an exception as these were much more slowly cleared from circulation. In general the
clearance t½ from organs is long and there is some clearance of nanoceria months after
administration that seems to be due to dissolution and some redistribution.
The pharmacokinetics of parenteral non-intravenous nanoceria administration
When 3 to 5 nm primary particle sized-fluorescent-tagged nanoceria was IP injected into
CD-1 mice at the same dose (0.5 mg/kg) and schedule (2 to 5 weekly injections) as given IV
(above) 19, ~ 4.2, 1.25, 0.02 and 0.01% of the dose was in the liver, spleen, lung, and kidney,
respectively, 7 days after the last dose 19. These results suggest some uptake of nanoceria
from the peritoneal cavity, or nanoceria dissolution and cerium uptake.
The pharmacokinetics of the cerium ion
The pharmacokinetics and distribution of nanoceria are quite different than cerium,
consistent with observations of many nanomaterials that their properties are different from
their solute or bulk forms. Approximately 2.5% of IV cerium chloride was excreted in urine
during the first day, decreasing to ~ 0.1% by day 14, resulting in elimination of ~ 5.5% in
the first 15 days, whereas fecal excretion was ~ 4.5% of the dose 7 days after injection, ~
42% in the first 15 days 32. In another study, less than 1% of IV injected cerium was
excreted in the urine over 4 days 33. In the first 7 days after IV cerium chloride
administration total cerium eliminated in urine and feces of rats was 0.02 and 0.85% of the
dose, respectively 18. In contrast, only 0.01% of a 30 nm ceria was eliminated in urine
during the first 14 days after its dosing, and only 0.4% appeared in the feces 18. One h after
IV injection of cerium chloride 10% remained in serum, which was then cleared with a t½ of
~ 10 h 33 and initial and beta t½s of 0.6 and 16 h 26. In contrast, > 98% of 15, 30, and 55 nm
ceria was cleared from blood within minutes and 10 minutes after a 1 h IV infusion of 5 nm
ceria ~ 35% was in blood, which was cleared with an initial and beta t½ of 0.4 and 124 h 26,
as noted above. Fifteen days after an IV injection of cerium chloride, 20, 16, 2, and 2% was
in the skeleton, liver, kidneys, and gastrointestinal (GI) tract, whereas 0.7, 0.5, 0.08, 0.08,
and 0.05% was in the muscle, spleen, lung, testes, and heart 32, 34. In contrast, nanoceria is
predominantly cleared into MPS organs, the liver, spleen, and bone marrow 13, 18, 19, 22, 23.
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During the first 8 days after inhalation of 1.5 µm mean aerodynamic diameter cerium
particles the t½ of cerium in the liver was estimated to be 11 and 17 days, with 0.5 to 1% of
the hepatic burden excreted daily, accounting for approximately 0.09% of the initial cerium
body burden 35, 36. In contrast, the percent of the dose of a 30 nm ceria in the liver decreased
from 7 to 30 days after a single IV administration, but over the next 90 days did not decrease
further, while there was little decrease in the bone marrow and an increase in the spleen 18.
What we know:
• After IV infusion, nanoceria rapidly translocates from the blood to the liver, spleen,
and bone marrow, from which clearance is slow. Appreciable entry of nanoceria
into brain parenchyma was not seen with ≥ 5 nm ceria, but was observed in the
cerebellum with a 2.9 nm ceria.
Knowledge gaps:
• What is the fate of nanoceria in the vascular compartment that has associated with
the vascular endothelial cells? Does it dissociate from those cells, perhaps due to
protein coating, to re-enter circulating blood and then be cleared by macrophages
into MPS organs?
• What are the long term fate and effects of nanoceria, for the life of the mammal,
given it is quite insoluble and persistent, and its expected low exposure
concentration in air and food?
The toxicodynamics of intravenously-administered nanoceria
During the IV infusion of 50, 250, and 750 mg/kg of an ~ 30 nm platelet ceria to rats,
clinical toxicity was only observed in some rats receiving the 750 mg/kg dose; bruxism and
excessive licking were seen in some rats receiving all doses 13. No adverse effects were seen
after the infusion and no animals died within 20 h. Kidney and liver weights increased.
There was a dose-dependent increase of activated Kupffer cells. This study revealed little
acute toxicity from very large doses given intravenously. Intravenous administration of 175
and 250 mg/kg of a 5 nm ceria resulted in mortality within 1 h, whereas 85 mg/kg was
tolerated, with no mortality to 30 days 16, 22. An infusion of 100 mg/kg 30 nm ceria
produced mild distress (tachypnea, skittish, not resting well). Doses of 78 to 250 mg/kg of
55 nm ceria produced significant toxicity (dyspnea, lethargy), whereas doses of 100 mg/kg
of the 5, 15, and 30 nm ceria and 50 mg of the 55 nm ceria did not result in mortality, further
demonstrating low acute toxicity of IV nanoceria 22.
Compared to the cerium ion, nanoceria is much less toxic. The LD50 of CeCl3•6H2O in mice
was ~ 13 mg/kg 33. Intravenous injection into dogs of 50 mg/kg cerium chloride resulted in
deterioration over 21 days 37. In contrast, doses up to 100 mg/kg of 5, 15, 30, and 55 nm
ceria were tolerated 22.
To assess the potential to produce subchronic toxicity, extensive daily cage side
observations were conducted for 90 days after a single 85 mg/kg 30 nm ceria IV infusion.
These revealed no adverse effects. The nanoceria-treated rats gained 5% less weight during
Yokel et al. Page 7
Environ Sci Nano. Author manuscript; available in PMC 2015 October 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
the first 7 days after treatment than controls. This 5% differential persisted relatively
unchanged throughout the study 18.
Histological assessment of toxicity to the liver 1 and 20 h after IV infusion of 50, 250, and
750 mg/kg of an ~ 30 nm ceria showed some hepatocyte degeneration 20 h after the 2
highest doses 13. Intravenous infusion of 85 mg/kg of a 30 nm ceria produced nanoceria-
laden Kupffer cells. These stimulated CD3+ lymphocyte proliferation in the sinusoids to
form granulomata, composed of ceria-laden Kupffer cells and a few non-ceria accumulating
mononuclear cells, that were seen 30 days after the single nanoceria dose and persisted
without great resolution or progression to 90 days after dosing 18, 38. The granuloma were of
the non-necrotizing type and did not progress to frank hepatic necrosis. There was a 50%
increase in serum ALT levels, but apoptosis was not seen 20 h to 90 days after nanoceria
dosing. There was an increase of cell proliferation, particularly 90 days after nanoceria
dosing. The hepatic localization and effects of a 5 nm ceria were similarly studied after a
single IV administration of 85 mg/kg 39. Liver cerium increased to 51% of the dose,
decreasing to 44% 30 days later (Figure 1). Similar to the 30 nm ceria, agglomerations of
nanoceria (up to 2 um) were seen in activated Kupffer cells. Some of these intermingled
with CD3+ cells and mononucleated cells to form granulomas. Although nanoceria
agglomerates appeared near the bile canaliculi, translocation into the biliary system was not
observed, consistent with the lack of significant decrease of cerium in the liver up to 30 days
after its administration.
In contrast to the above findings, no evidence of liver pathology was observed in mice on
day 35 that received a total IV dose of 130 mg/kg of a citrate/EDTA coated 2.9 nm ceria
over 35 days 24.
Histological examination of H & E stained thin sections of the brain, lungs, liver, kidneys,
spleen, and pancreas 7 days after IV injection of a 3 to 5 nm primary particle sized
nanoceria, 0.1 or 0.5 mg/kg, and 15 days after a second injection, revealed no lesions 20.
After IV, IP, or oral administration of 3 to 5 nm primary particle size nanoceria, 0.5 mg/kg
weekly for 2 or 5 weeks, histology assessment only revealed a reactive Peyer’s patch in the
small intestine of one IP dosed mouse and a pulmonary hemorrhage in one IV dosed mouse.
The authors concluded that this nanoceria dose did not cause overt pathology 19. Intravitreal
injection of 344 ng of nanoceria into each eye of rats did not produce adverse effects up to
120 days later, determined as retinal thickness or function 40.
One and 20 h after the IV infusion of 50, 250, and 750 mg/kg of an ~ 30 nm ceria, BBB flux
markers showed non-significant change, nor was there microscopic evidence of BBB
disruption 13. Nanoceria effects on BBB integrity were further assessed in rats up to 20 h
after a single IV infusion of the 5 nm ceria described above 16, 17. No adverse effects on
BBB integrity were seen other than a slight, significant, increase of horseradish peroxidase
above control 20 h after the 5 nm ceria 16. Intra-arterial injection of up to 500 µg/ml 5 nm
ceria for 120 seconds at 20 ml/min did not alter BBB integrity 14.
Twenty h after IV infusion of 250 and 750 mg/kg of an ~ 30 nm ceria, brain protein-bound
4-hydroxy 2-transnonenal (HNE, formed by lipid peroxidation of unsaturated acyl chains of
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phospholipids) was elevated in the hippocampus but not cortex or cerebellum. In contrast, 3-
nitrotyrosine (3NT, produced by nitric oxide reaction with tyrosine) was not changed, and
protein carbonyls (a biomarker of oxidative stress) were decreased in the cerebellum 13. To
further pursue this nanoceria effect, multiple oxidative stress markers (HNE, 3NT, protein
carbonyls, glutathione reductase [GR] level and activity, glutathione peroxidase [GPx] level
and activity, superoxide dismutase [SOD] level and activity, and catalase level and activity)
were determined 1 and 20 h after the 5 nm ceria. They showed little change, limited to an
increase of catalase level 1 h and activity 20 h in the hippocampus and a decrease of catalase
activity 1 h in the cerebellum 16. Thirty days after the 5 nm ceria infusion, protein carbonyl
and heat shock protein 70 (Hsp70) levels were increased, and GPx and catalase activity and
the reduced/oxidized glutathione (GSH/GSSG) ratio were decreased in the hippocampus 17.
3NT and inducible nitric oxide synthase (iNOS) levels were increased, and GR level
decreased, in the cortex. Protein carbonyl and heat shock protein 70 levels were increased,
and GPx levels and activity and catalase levels decreased in the cerebellum. These results
suggest greater pro-oxidant effects on the brain 30 days after a 5 nm ceria than at earlier
times, in the absence of nanoceria entry into brain parenchyma.
To extend these findings, numerous measures of oxidative stress were measured in rat
hippocampus 1 and 20 h and 1, 7, 30, and 90 days after a single IV administration of 30 nm
ceria 41. Protein carbonyl, 3NT, heme oxygenase-1 (HO-1), and Hsp70 levels decreased in
the first day, then increased up to day 30, whereas GPx and catalase levels and activity
showed the opposite trend, increasing in the first day, followed by a decrease up to day 30.
IL-1β levels were elevated from days 1 to 30, and pro-caspase-3 levels increased at day 30
and LC-3 AB levels increased from days 7 to 30, indicating apoptosis and cell proliferation.
Ninety days after the single nanoceria infusion, nearly all endpoints returned to control
levels. These trends can be explained by induction of Tier 1 oxidative stress responses 1 and
20 h after nanoceria, induction of Tier 2 oxidative stress response after 1 to 30 days, and
induction of Tier 3 oxidative stress response at 30 days, as previously described 42.
Additionally, they suggest activation of a Tier-4 response that restores the cellular redox
balance 90 days after the single nanoceria administration. Release of factors such as pro-
inflammatory cytokines may lead to these effects distal to the site of nanoceria deposition.
These responses were seen in the absence, or at most a very few particles, of nanoceria in
the brain 16, 17, 41.
Nanoceria biotransformation in vivo
To address if there are changes in the Ce3+/Ce4+ ratio 43, 44, electron energy loss
spectrometry (EELS) of the surface of a 5 nm ceria was determined. It showed Ce3+
enrichment, which was not changed after the nanoceria was in the vasculature of the rat’s
brain for 20 h 16. A 30 nm ceria showed similar Ce3+ enrichment on its surface. Its core had
a greater percentage of Ce4+ 18, 38. These results did not show nanoceria biotransformation
over this short time. However, when the liver was examined by HRTEM 90 days after a
single IV infusion of a 30 nm ceria, the ceria exhibited rounded edges and corners. Clouds
of 1 to 3 nm, (111) and (200) faced, crystalline ceria near the partially biodegraded
nanoceria were seen, suggesting a dissolution-precipitation process. EELS showed increased
surface Ce3+ consistent with ultrafine nanoceria particles, suggesting greater anti-oxidant
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potential 45. These observations suggest nanoceria bioprocessing to a more stable,
potentially more beneficial, nanoceria form.
What we know:
• Intravenous nanoceria has low acute toxicity, ~ 1 order of magnitude less than ionic
cerium.
• Oxidative stress leading to inflammation is the key toxicological effect, possibly
leading to granuloma at high dose levels.
Knowledge gaps:
• There is hardly any information whether repeated systemic nanoceria exposure
results in a change in response due to prior exposure.
• What mediates the changes in brain stress responses in the absence of nanoceria in
brain parenchyma?
• How reversible are the observed adverse responses to nanoceria exposures?
Pulmonary deposition and response
Introduction
The most likely route of human unintentional exposure to nanoceria is through inhalation.
Following inhalation exposure, nanoceria, being poorly-soluble in body fluids 46, 47,
deposits within the respiratory tract based on physical properties related to its size
distribution and agglomeration/ aggregation state 48. Ceria detected in diesel exhaust
emissions from a nanoceria-based fuel additive was found to be of nanoscale size (<100
nm) 3, 49, 50. Knowledge of the potential health effects associated with the use of nanoceria,
including its use as diesel fuel additive, is rather limited 51.
Deposition, translocation, and clearance
Particle deposition following inhalation is dependent on the particle thermodynamic and
aerodynamic size, and agglomerate size, generally measured as mass mean (aerodynamic)
diameter (MMAD) 48. At low to zero air velocity, diffusion dominates nanoparticle
deposition rate. However, measurement of MMAD rather than primary particle size
distributions and amounts does not predict the delivered dose in the human respiratory tract.
In general, nanoscale particles with a primary diameter 1 to 100 nm penetrate deeper into the
lung than do larger size particles. Nano-sized particles are deposited by diffusion, primarily
in the alveolar and tracheal bronchial regions. Due to their poor solubility they are slowly
cleared 3, 52. Some of the deposited particles are cleared via the mucociliary escalator to the
pharynx and ingested, while others are transported to the tracheobronchial and pulmonary
lymph nodes via penetration through the airway epithelium 3, 48. Therefore, inhalation of
particles leads to secondary exposure to the GI tract and potential uptake from this organ
system, although nanoceria uptake from the GI tract is extremely low (see below). Studies in
humans on absorption of microscale ceria following inhalation exposure have not been
identified. However, case reports and retrospective occupational investigation provide
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support for the limited absorption of microscale ceria deposited in the lung following
inhalation exposure 52. It is possible that nanoceria may dissolve more easily than
microscale particles due to their larger surface area 53. However, given the biopersistence of
nanoceria in the lung, significant nanoceria dissolution seems unlikely.
Much more attention has been paid to the inhalation of nanoceria than its ingestion, since
cerium and nanoceria are poorly absorbed from the intestine 53, described below. For
microscale ceria, it is known that the primary targets after inhalation are the lung and the
associated lymph nodes. Other organs could also be affected through the blood and intestine
following their clearance or translocation from the lung. After absorption into circulation,
nanoceria may distribute to the liver, skeleton, spleen, and kidney, as summarized 53. Two
hundred µg nanoceria (6.6 nm primary particle size, 12.8 nm hydrodynamic mean diameter;
97% 24 nm and 3% 88 nm in water, ζ =30 mV) labeled with 141Ce was introduced by
intratracheal instillation into male Wistar rats and translocation evaluated 6 h to 28 days
later 46. Of the heart, liver, spleen, kidney, brain, testes, and stomach (cerium in the stomach
decreased over time), liver had the highest 141Ce at 28 days (~ 0.1% of the dose) showing
low translocation from the lung. Studies in Wistar rats exposed to cerium chloride aerosol
(mean diameter 0.1 µm) showed that cerium was deposited in the lysosomes of alveolar
macrophages (AMs) 54, 55.
The process of phagocytosis by macrophages is in competition with uptake of particles by
alveolar epithelial cells (which can result in increased access of particles to the interstitium,
where they may cause damage). Some studies have shown that small particles are more
readily taken up by epithelial cells than by macrophages and show greater rates of transfer
across the epithelium 3. This route results in interstitialisation with persistence in the
submucosal centriacinar region, or transfer to the lymph nodes. The uptake of 20 to 50 nm
ceria, 100 ng/ml to 100 µg/ml, by human lung 3T3 fibroblasts was measured in vitro.
Nanoceria internalization occurred linearly with exposure time at concentrations as low as
100 ng/g cells. Nanoceria was not present outside of the vesicles or flowing freely in the
cytoplasm and was present exclusively as agglomerates. The size of the nanoceria (including
the agglomeration state) greatly affected the amount of cerium incorporated into the cell,
with more efficient uptake of larger particles and agglomerates (at the same mass
concentration). Particle size was a more important factor in uptake than particle density and
total surface area 56, consistent with lack of saturation of processes moving nanoceria across
membranes, noted above.
The tissue distribution of inhaled nano- and microsized ceria particles in rats was assessed in
a 28-day exposure study 57. Powder aerosolization resulted in comparable MMAD (1.02,
1.17, and 1.40 µm) for the three types of ceria despite marked differences in primary particle
size of 5 to 10, 40, and< 5000 nm, respectively. At 24 h after a single exposure,
approximately 10% of the inhaled dose was measured in lung tissue, in agreement with
estimations by a multiple path particle dosimetry model. Each ceria sample also translocated
to liver, kidney, spleen, brain, testis, and epididymis after a single 6 h exposure. No
consistent differences in pulmonary or extrapulmonary deposition among the nano- and
microparticles (as defined by their primary particle size) were observed, most likely as a
consequence of their overlapping aerodynamic sizes. Repeated exposure to ceria resulted in
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low but statistically significant particle accumulation in extra pulmonary tissues. In addition,
tissue clearance was shown to be slow, and, overall, insignificant amounts of cerium were
eliminated from the body 48- to 72-h post-exposure. In conclusion, no clear effect of the
primary particle size or surface area on pulmonary deposition and extrapulmonary tissue
distribution could be demonstrated. This is most likely explained by a similar aerodynamic
diameter of the ceria particles in air because of the formation of agglomerates and
irrespective of possible differences in surface characteristics. This confirms findings 58 that
it is highly likely that a substantial fraction of the test atmospheres were micron sized when
they entered the deep lung.
In an inhalation study in mice, exposure of nanoceria (15 to 30 nm primary diameter and 30
to 50 m2/g specific surface area [SSA]) for 0, 7, 14, or 28 days at an aerosol concentration of
2 mg/m3 resulted in significant bioaccumulation in pulmonary and extrapulmonary tissues,
even 30 days after inhalation exposure 59. Despite the small primary diameter, the test
aerosol was characterized by a MMAD of 1.4 µm and a wide distribution, as indicated by a
geometric standard deviation of 2.4. Although a substantial fraction of these particles would
not have been able to reach the lower airways and lungs due to their large size, it is
noteworthy that some nanoceria could be distributed through the body and that a slow
clearance was reported.
The implications of size were further investigated as the uptake of 15, 25, 30, and 45 nm
ceria into human bronchial epithelial cells (BEAS-2B). It was observed that nanoceria
penetrated into the cytoplasm and was found in the perinuclear region as aggregated
particles. However, there were no clear signs that primary particle size in this small range
affected uptake 4.
J774A.1 murine macrophages were studied to determine if 3 to 5 nm ceria could be
incorporated intracellularly. Nanoceria particles and agglomerates localized in phagosomes
and cytosol, suggesting that one mechanism of uptake is through phagocytosis and that the
particles may thereafter diffuse into the cytosol. The presence nanoceria clusters in the
outermost edges of the macrophages suggests that single nanoceria particles may also
diffuse directly through the membrane 20.
Nanoceria was shown to be internalized through clathrin- and/or caveolae-mediated
endocytosis in human keratinocytes and lung epithelial cells (BAES-2B) as well as in mouse
macrophages (RAW 264.7 cells) 60, 61. These and other studies demonstrated that nanoceria
co-localizes with mitochondria, lysosomes, endoplasmic reticulum, and the nucleus as well
as occurring free in the cytoplasm 62–64.
The results described above are not very specific for nanoceria and apply to most, if not all,
granular low solubility particles. Uptake is largely driven by their physical properties.
Clearance of inhaled particles depends on their site of pulmonary deposition, their physical
and chemical properties, and their impact on biological systems. Phagocytosis of particles is
the major mechanism of uptake of insoluble structures such as nanoceria into a cell and the
ability will vary among various cell types, macrophages being the most active. This is
typically a process that occurs in macrophages, but free particle transport, especially of
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nanosized particles, cannot be excluded. No information is available concerning pleural
transfer of nanoceria. Another pathway to remove particles is by dissolution, followed by
absorption in the blood. Through this process, cerium ions might be transported to and may
accumulate in various organs. Dissolution might occur either within the AMs or in the
extracellular fluids. The dissolution rate is proportional to the particle surface: smaller
particles are more likely to be dissolved than larger particles. However, nanoceria is not very
soluble in lung lining fluid. In addition, many metallic particles (including cerium
compounds) have been shown to dissolve and precipitate inside macrophages as phosphate
compounds, thus preventing movement into the bloodstream 3.
Nanoceria is removed from the lungs to the GI tract through mucociliary clearance 3.
Therefore, a primary route of elimination of inhaled nanoceria is through the feces, with
small amounts eliminated in the urine 52. Rapid elimination by mucociliary clearance was
shown for nanoscale particles in a study in hamsters exposed to ceria aerosols with an
aerodynamic diameter of 60 and 110 nm with decreases in initial body burden of 60 and
95%, respectively, 4 days after exposure 52,65.
Some insight into the fate and persistence of worker inhalation of ceria particles can be
derived from a case report. Cerium-containing particles accounted for 70% of the particles
in AMs in bronchoalveolar lavage (BAL) fluid (BALF). Particles containing cerium were
seen in interstitial macrophages and elastic fibers of lung tissue 15 years after termination of
occupational exposure to a ceria abrasive powder 66. These results suggest prolonged
persistence of ceria in the lung, which is supported by a t½ of 235 days after whole body
exposure inhalation of 25 mg/m3 of NM-212, a 40 nm uncoated commercial nanoceria 67.
The implications of nanoceria particle accumulation for systemic toxicological effects after
repeated chronic exposure via ambient air are significant and require further exploration to
elucidate the extent and time course of such translocation. In addition these observations are
of importance to future risk assessment.
Toxicological data from in vivo inhalation toxicity studies: Acute exposure (hours up to
one day)
There are very little data published on short-term (up to one day) inhalation exposures. A 4 h
inhalation toxicity study of nanoceria (55 nm primary size and 30 to 50 m2/g surface area) in
rats following OECD TG403 was reported 68. The test atmosphere was characterized as 55
nm and 641 mg/m3 and a MMAD of 2.28 µm. Neutrophils and AMs overloaded with
phagocytosed nanoceria were observed along with non-phagocytosed free nanoceria that
was deposited over the epithelial surfaces of the bronchi, bronchiole, and alveolar regions of
lungs within 24 h of post-exposure, and were consistent throughout the 14 day observation
period. Well distributed, multifocal, pulmonary microgranulomas, due to impairment of the
clearance mechanism leading to nanoceria biopersistence, were observed at the end of the 14
day post-exposure period. These results suggest that acute nanoceria exposure via the
inhalation route may induce cytotoxicity via oxidative stress and may lead to a chronic
inflammatory response, but it must be emphasized that the levels of exposures are orders of
magnitude higher than one might expect in a work place environment. Another study
exposed rats by inhalation 2 h/day for 4 days to 2.7 mg/m3, that was 1% of the total inhaled
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dose use in the previously described study 69. The MMAD was 281 nm. It is worth noting
that this is the only published study that used a truly nanoscale aerosol exposure atmosphere
generated using an industry relevant flame spray pyrolysis system (Harvard VENGES
system) 70. BAL levels of neutrophils increased 6 fold 24 h post-exposure indicating
inflammation, while BAL activity of LDH increased 2 fold indicating cytotoxicity. These
markers of pulmonary response returned to control levels 84 days post-exposure.
A single intratracheal dose of 0.15 to 7 mg/kg nanoceria was delivered to male Sprague
Dawley rats 71, 72. Pulmonary inflammation with AMs containing nanoceria was reported.
Fibrogenic responses, evidenced by increased hydroxyproline content, a marker for fibrosis,
were induced 84 days after the 3.5 and 7 mg/kg doses. The results showed that nanoceria
induced fibrotic lung injury in rats, suggesting it may cause potential health effects. It was
also observed that at these two dose levels the inflammatory effects induced by nanoceria
did not return to control 84 days after exposure, suggesting a relatively low clearance rate. In
contrast, aspiration of nanoceria (20 µg/mouse) did not affect BAL neutrophil counts or
levels of inflammatory mediators (MCP-1 and IL-6) 73. It should be noted that after
accounting for the rat lung being approximately 10 times larger than the mouse lung, the
nanoceria dose used in this study 73 was still about 10-fold lower than reported by others 72.
This implies that the LOAEL for a single dose to the lung is in the order of 0.6 g/kg bw.
Effects observed in kidneys 74 suggest there is risk of development of adverse effects at
distal sites. Systemic effects were also noted when rats were intratracheally instilled with
nanoceria (up to 7 mg/kg). However, this study suggested that this single high dose exposure
only resulted in liver toxicity, as no effects on heart, spleen, and kidney, based on organ
weights and serum biochemistry, were reported 75.
Toxicological data from in vivo inhalation toxicity studies: Sub-acute exposure (several
days to weeks)
Preliminary results of a toxicity study in rats were described 76. Exposure by inhalation for 5
days, 6 h/day, to 27 nm MMAD (Gsd 1.6) ceria caused pronounced effects at a mass
concentration of 0.14 mg/m3 compared to the aggregated 0.80 um MMAD (Gsd 1.4)
nanoceria or the 0.90 um MMAD (Gsd 1.5) microceria. Increased levels of biochemical
parameters and leukocytes in BALF were seen. Although the spark-generated method may
not be widely employed to commercially produce nanoceria, it provides useful information
on the effects of singlet nanoceria particles. In contrast, aggregated ceria particles of similar
primary size induced less and milder changes in BALF at 1.4 mg/m3, a more than 10 times
higher mass concentration. Similar mass concentration of the 0.90 um MMAD ceria failed to
induce any changes in BALF. These results suggest that true nano-sized ceria aerosols are
more toxic than such particles in aggregated form and that the latter are more toxic than
micro-sized particles of the same material. To what extent this is due to the differences in
(local) pulmonary deposition is not yet fully understood.
The effects of coating ceria nanoparticles with silica (silicon dioxide; SiO2) were
determined 69. Male Sprague-Dawley rats were exposed to 2.7 mg/m3 of silica-coated ceria
(21 nm), uncoated ceria (17 nm), or particle-free environments (controls) (2 h/day, 4 days).
Interestingly, while animal exposure to uncoated nanoceria induced considerable PMN
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infiltration (an indicator of inflammation), compared with the control group, PMN levels for
the silica-coated scenario were similar to the particle-free control group levels. These results
suggest that freshly generated nanoceria particles possess at least some surface chemistry
that results in an inflammatory response which can be prevented by SiO2. This is discussed
in more detail below in Engineering safer by design nanoceria.
The comparative hazard of two nanoscale (5 to 10 and 40 nm) and one microscale (<5000
nm) ceria previously studied 57 were assessed in 28-day inhalation toxicity studies in rats 77.
All three materials gave rise to dose-dependent pulmonary inflammation and lung cell
damage but without gross pathological changes on the day following the last exposure.
Epithelial cell injury was observed 14 to 21 days following nanoceria exposure. There was
no evidence of systemic inflammation or other hematological changes following exposure to
any of the three particles. The comparative hazard was quantified by application of the
benchmark concentration approach 77. The relative toxicity was explored in terms of three
exposure metrics. When exposure levels were expressed as mass concentration, one of the
nanoceria was the most potent material, whereas when expression levels were based on
surface area concentration, micro-sized ceria induced the greatest extent of pulmonary
inflammation/damage. Particles were equipotent based on particle number concentrations. In
conclusion, similar pulmonary toxicity profiles, including inflammation, were observed for
all three materials with little quantitative differences. Systemic effects were virtually absent
in a 28-day OECD TG 412 inhalation study in which the effect of 10 µg/ml 16 nm ceria
added to diesel fuel was investigated. Of interest, a recent study reported that use of
nanoceria as a fuel additive reduced the number of particles generated by a diesel engine and
decreased the size of atherosclerotic plaques resulting from inhalation of diesel engine
exhaust in a rodent model 50.
An inhalation study in mice showed that nanoceria can induce pulmonary and
extrapulmonary toxicity 59. Male CD1 mice were subjected to nose-inhalation exposure of
nanoceria (15 to 30 nm primary diameter, MMAD 1.4 µm, and 30–50 m2/g SSA) at an
aerosol concentration of 2 mg/m3 for 0, 7, 14, or 28 days with 14 or 28 days of recovery
time. Markers of lung injury and pro-inflammatory cytokines (IL-1β, TNFα, IL-6, and
macrophage inflammatory protein-2) in BALF, oxidative stress in lungs, bioaccumulation,
and histopathology of pulmonary and extrapulmonary tissues were assessed. BALF analysis
revealed the induction of pulmonary inflammation, evident by an increase in the influx of
neutrophils with a significant secretion of pro-inflammatory cytokines. This led to oxidative
stress generation and cytotoxicity, evident by induction of lipid peroxidation, depletion of
glutathione, and increased BALF LDH and protein. Histopathological examination revealed
that inhaled nanoceria was located throughout the pulmonary parenchyma, inducing a
severe, chronic, active inflammatory response characterized by necrosis, proteinosis,
fibrosis, and well-formed discrete granulomas in the pulmonary tissue and tubular
degeneration leading to coagulative necrosis in kidneys. The study also indicated that
significant systemic effects were only detected after 28 days and that these responses
remained present during the recovery phase. More subtle effects were also reported for
shorter durations, and these became worse with longer exposure durations. Pulmonary
responses remained evident during the recovery period. From this, one can conclude that due
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to an imbalance in deposition and clearance, accumulation can occur leading to a (local)
dose that causes toxicity and that clearance is rather slow. In other words, there is a risk that
long term exposure to low levels of nanoceria may eventually lead to adverse health effects.
Very few studies have assessed the effects of nanoceria exposure in organs other than the
lung. The effects of nanoceria (4 nm primary size, 81 m2/g surface area) on microcirculation
were studied as the reactivity of isolated rat coronary and mesenteric arterioles 74. Animals
received intratracheal exposure (0 to 400 µg/rat suspended in saline with 5% serum; 197 ±
77 nm). BALF and arterioles were collected 24 h post exposure. The authors calculated that
the highest dose is equivalent to the deposition in a person performing light work for 30
years and an exposure of 5 µg/m3. Pulmonary cytotoxicity and inflammation were recorded
in the 100 and 400 µg exposure groups, whereas microvascular dysfunction was observed at
lower levels where no pulmonary responses were recorded. The underlying mechanism for
these observations is not yet known, although it appears to involve depletion of
endothelium-derived nitric oxide. The fact that pulmonary responses are less sensitive to
lung exposure than systemic vascular responses should be considered in risk assessment.
Toxicological data from subchronic inhalation toxicity studies (several weeks to months)
Toxicological data are available from one subchronic inhalation exposure study using
Sprague-Dawley rats exposed to microscale ceria (MMAD = 1.8–2.2 µm, geometric
standard deviation = 1.8 to 1.9, and at concentrations of 0, 5, 50.5, or 507.5 mg/m3 for 6 h/
day, 5 days/week for 13 weeks 52,78. This study observed an increased incidence of alveolar
epithelial hyperplasia. Histological examination revealed dose-related alveolar epithelial and
lymphoid hyperplasia and pigment accumulation in the lungs, lymph nodes, and larynx of
male and female rats at ≥ 5 mg/m3 52,78. The metaplasia evident in the larynx was
interpreted by the study pathologist as adaptive and reversible. This study suggested that
exposure to ceria is associated with antigenic stimulation; however, they did not discuss the
possibility of non-antigenic stimulation. This study identified a LOAEL of 5 mg/m3 in rats,
based on the increased incidence of lymphoid hyperplasia in the bronchial lymph nodes of
male and female rats. A NOAEL was not identified.
Toxicological data from chronic (> 1 year) inhalation toxicity studies
There are no data on the effects of chronic exposure to nanoceria. However, at the request of
the German Government, BASF in Germany started in spring 2013 to perform a 2-year
exposure study following OECD TG 453 including four concentrations using a nanoceria
(NM-212) with a primary particle diameter of 40 nm and a BET surface area of 27 m2/g. It
is dosed at 0.1, 0.3, 1, and 3 mg/m³. The highest concentration is expected to result in lung
overload. Biodistribution and effects will be determined after 3 month, 1 year, and 2 year
exposure, with 3 animals per time point. This material has been utilized in other inhalation
studies 77.
Mechanism of action of respiratory toxicity
Toxic effects of nanoceria may be attributed to two actions: chemical toxicity based on the
chemical composition, or due to stress/mechanical irritation or stimuli caused by the surface,
size, and/or shape of the particles (physical aspects). However, it is not straightforward to
Yokel et al. Page 16
Environ Sci Nano. Author manuscript; available in PMC 2015 October 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
differentiate between these two types of cytotoxicity. Solubility greatly affected cell culture
response to nanoceria, which was insoluble 79. An in vitro toxicity assay was used to
investigate the involvement of the oxidative stress responding signal transduction pathway
and transcription factors in the toxicity of nanoceria in BEAS-2B cells 80. They found that
nanoceria may exert toxicity through oxidative stress, as it caused significant increases in
cellular reactive oxygen species (ROS) concentrations, subsequently leading to strong
induction of HO-1 via the p38-Nrf-2 signaling pathway 80. ROS mediated DNA damage and
cell cycle arrest are also suggested to play a major role in nanoceria-induced apoptotic cell
death in A549 cells 81. Although it was claimed that nanoceria can act as a free radical
scavenger due to reactive sites on its surface, prolonged exposure to nanoceria further
induces the production of 8-oxoguanine. This may explain the nanoparticulate oxidative
stress and resulting altered gene expression found in another study 82. As seen in these
studies the biological mechanism of nanoceria’s action has been a bit contradictory, which
may reflect some as yet unknown unique chemical property of this novel material. One
suggestion is the method of nanoceria production. It has been observed that room
temperature synthesis of nanoceria results in anti-oxidative activity whereas high
temperature synthesis often results in pro-oxidative activity 83. Other nanoceria chemical
factors as well as biological status may affect the response to nanoceria.
What we know
• In several reports, pulmonary exposure to nanoceria has resulted in pulmonary
inflammation, alveolar interstitial fibrosis, and alteration in the ability of the
systemic microvasculature to respond to dilators. However, other studies report
little or no adverse pulmonary response to exposure of the lung to nanoceria but a
systematic comparison of the delivered dose is lacking. The vast majority of the
published studies have assessed the toxicity of agglomerates of nanoceria, which
would classify nanoceria as low toxic material. The exception is a single study in
which rats were exposed to 27 nm ceria particles which appears to result in marked
toxicity compared to larger size aggregates.
Knowledge gaps
• What aspects of ceria cause toxicity: surface reactivity and aggregate size?
• Nanoceria appears to be quite insoluble and persists in the lungs. What is the rate of
clearance from the lung and translocation to, and accumulation in, other organs?
Oral exposure
Oral exposure to nanoceria might occur in an occupational setting, which might employ
nanoceria in a pure form, or by environmental exposure, such as nanoceria associated with
diesel fuel combustion. No relevant literature using acellular or in vitro models was found
addressing nanoceria uptake from, or effects on, the GI tract. Particle absorption from the
intestine results from diffusion though the mucus layer, initial contact with enterocytes or M
(microfold or membranous specialized phagocytic enterocyte) cells, cellular trafficking, and
post-translocation events 84. Absorption of colloidal bismuth subcitrate and colloidal
(maltodextran) gold particles appeared to occur through regions of gastric epithelial
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disruption 85 or penetration through gaps created by enterocytes that died and were being
extruded from the villus 86. Studies with other nanoscale materials have generally shown
very low absorption from the GI tract. Absorption inversely correlated with the size of 50
and 100 nm polystyrene 87 and 4 to 58 nm colloidal gold nanoparticles 86.
Oral bioavailability of nanoceria has been studied in rodents 19, 46, 88. Thirty nm ceria, 0.1 or
5 g/kg, was administered orally, suspended in water, to male SD rats, which were evaluated
1, 7, or 14 days later 88. No significant changes in hematology or serum biochemistry were
observed 1 day later. No deaths; lesions in the liver, lung, or kidney; or signs of
inflammation were seen up to 14 days. Cerium concentrations in the liver, kidney, spleen,
lung, testis, and brain were greatest in the lung, and decreased over 14 days, whereas cerium
concentrations in the other sample organs did not. Some lung cerium may have resulted
from lung uptake during nanoceria administration rather than translocation from the GI tract.
Cerium in the sampled organs accounted for ~ 0.02% of the 0.1 g/kg dose. Nanoceria (6.6
nm, 12.8 nm hydrodynamic size; 97% 24 nm and 3% 88 nm in water, ζ = 30 mV) labeled
with 141Ce was introduced into the GI tract of male Wistar rats, which were evaluated 1, 3,
or 7 days later 46. Of the heart, liver, spleen, kidney, brain, testes, muscle, bone, blood, and
lung, liver had the highest 141Ce. Approximately 0.0003% of the dose was accounted for in
these 10 tissues and blood, showing very low oral absorption. Nanoceria produced by
methods that result in crystalline 3 to 5 nm primary particles 20 were functionalized with
carboxyfluorescein that did not alter the individual particle size. CD-1 mice were given 0.5
mg/kg nanoceria weekly for 2 or 5 weeks suspended in saline via a tube inserted into the
stomach through the mouth 19. Mice were evaluated 1 week after the last dose.
Approximately 0.2 and 0.025% of the dose was in the lung (that was most likely due to the
gavage procedure or aspiration) and spleen, respectively, with less in the liver, kidney
(where clusters were seen in lysosomes), and heart. None was detectible in the brain.
Approximately 98% of the ceria appeared in the feces. None was detectible in the urine.
Compared to 0.03% cerium ion absorption within 3 days after its oral introduction 89 and a
report of no intestinal reabsorption 36, the oral absorption of nanoceria does not appear to be
different from ionic cerium. Nanoceria that had a hydrodynamic diameter of 53 nm but
extensively agglomerated in reconstituted hard water was ingested by C. elegans but could
not be detected inside cells 90. It can be concluded that the oral bioavailability of nanoceria
is extremely low. It is unlikely that a sufficient amount of intact nanoceria would be
absorbed to induce effects at distal sites.
What we know
• Nanoceria absorption from the GI tract is extremely low.
Knowledge gaps
• There is no information about repeated, low-dose exposure regarding accumulation
of nanoceria and potential effects.
• The influence of gastric acidity and GI juices on nanoceria dissolution and
absorption has not been reported.
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Dermal exposure
In the absence of organic solvents or stretching of the skin, there does not appear to be any
good evidence that topically-applied nanomaterial can penetrate through skin into
circulatory or lymphatic circulation 91. A commercial 9 nm primary particle size nanoceria
intended for use as a diesel fuel additive (Envirox®) was tested using an epidermis model
(EpiDerm® System) that contains human-derived epidermal keratinocytes 92. An unreported
concentration initially increased cell metabolism (MTT assay) 19% after 960 min exposure,
then decreased it 32 and 35% after 1200 and 1440 min. Based on comparison to a reference
material (stated to be 20% SLS; presumably sodium laureth sulfate, whereas the usual
positive control is 5% SDS (sodium dodecyl sulfate)), that reduced cell viability by 42% in
15 and 94% in 120 min, the authors concluded that their nanoceria did not have potential to
be an in vivo skin irritant. However, 0.06 g/l of 7 nm ceria decreased viability of human
dermal fibroblasts and produced concentration-dependent genotoxicity from 0.00005 to 0.02
g/l 28.
What we know
• Based on limited data, there is no evidence for nanoceria uptake through the skin or
that it is a skin irritant.
Knowledge gaps
• There is very limited published data on the kinetics and effects of nanoceria
interaction with skin.
Ocular exposure
No information was found on the effects of exposure of the surface of the eye (cornea) to
nanoceria. Intravitreal injection of 344 ng of nanoceria into each eye of rats resulted in a
much higher concentration in the retina than lens or eyecup tissue and an estimated t½,
determined from results obtained up to 1 year after the injection, of 525 days in the eye and
414 days in the retina 40.
What we know
• Nanoceria is retained in the eye for at least a year.
Knowledge gaps
• The extent of corneal exposure to nanoceria, and potential adverse outcomes, are
unknown.
Toxicological data from in vitro toxicity studies using cells
The cytotoxicity of nanoceria to human mesothelioma (MSTO-211H) and rodent fibroblast
(3T3) cells was determined by measuring metabolic activity and cell proliferation. Human
mesothelioma cells were found to be more sensitive than rodent fibroblast cells when
exposed to 6 nm ceria at different concentrations; metabolic activity and DNA content
decreased approximately 50% after 3 days of exposure. The mesothelioma and fibroblast
cells were, however, not completely killed at 30 µg/mL. After 6 days, the metabolic activity
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was not significantly altered and DNA content was increased slightly in the mesothelioma
cells. In the rat fibroblasts, the DNA content increased slightly and metabolism was not
significantly affected 79. Nanoceria toxicity was also investigated using the human BAL
carcinoma-derived alveolar type II cell line A549, which was exposed to 20 ± 3 nm ceria at
3 concentrations and durations 93. Cell viability decreased at all 3 concentrations over 3 days
dose- and time-dependently. The elevated ROS levels, increased lipid peroxidation,
increased membrane damage, and reduced antioxidant levels are evidence of oxidative stress
caused by nanoceria exposure 93.
The cytotoxicity of several metal oxide nanoparticles was compared using A549 cells 4. The
test materials fell into 2 distinct categories based upon surface area: those with a surface area
of 500 to 600 m2/g, including titanium dioxide and aluminum oxide, and those with a
surface area of 50 to 60 m2/g, which included copper oxide, ceria, and iron(III) oxide.
Unfortunately, no information on the size or shape of these particles was presented. They
used a synthetic model of human respiratory-tract lining fluid as well as an ascorbate-only
model. The experiment was repeated with soluble chloride salts. The chloride salts were
more toxic than the metal oxide forms, but there was no effect on cell viability of nanoceria
or soluble cerium chloride at concentrations up to 1000 µM. Nanoceria did not cause any
detectable cytotoxicity to epithelial cells based on lactate dehydrogenase (LDH; a biomarker
of cell damage and cytotoxicity) leakage and did not have a significant stimulating effect on
IL-8, which is typically involved in acute inflammation caused by particles 4. Ceria had, like
titanium oxide and aluminum oxide, very low effects on antioxidant depletion, whereas
copper oxide caused a 50 times higher depletion than the other metal oxides, most likely due
to its solubility and, therefore, the availability of free metal ions.
Exposure of A549 cells to nanoceria for 24 h did not affect cell viability 69. A physiological
model of the air-liquid interface of A549 cells was reported 82. For the exposure to
nanoceria (mean primary particle diameter of 5 to 20 nm), the culture plates were opened for
10, 20, and 30 minutes. LDH measurements and cell morphology did not show a difference
between exposed and control cells. The mean total lamellar body (storage sites for alveolar
surfactant synthesized by alveolar type II cells) volume per cell was found to be
significantly lower in cells exposed for 30 minutes compared to control cells and cells
exposed for 10 minutes. Another effect was the reduction of cell-cell contacts after
exposure, but the mechanism for this increased epithelial permeability was unknown.
Possibly, this indicates a disorganization of the tight junctions rather than dying cells.
Prolonged exposure to nanoceria further induced the production of 8-oxoguanine (a marker
for oxidative DNA damage). This may explain the nanoparticulate oxidative stress and
resulting altered gene expression found in other studies 82.
The cytotoxic effect of nanoceria was assessed using BEAS-2B cells, compared to other cell
lines (T98G and H9C2, derived from human brain fibroblasts and rat cardiomyocytes,
respectively) 94. BEAS-2B cell viability was decreased by treatment with nanoceria (15 to
45 nm) in a time- and dose-dependent manner. Differences in nanoceria size had no effect
on cell viability. No cytotoxic effects were found for T98G and H9C2 cells, suggesting that
nanoceria has cell-type dependent modes of action. ROS were generated in a dose-
dependent manner by 5, 10, 20, or 40 µg/ml 30 nm ceria particles in BEAS-2B cells. The
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levels of GSH were decreased in the nanoparticle-treated groups. Caspase-3, which plays a
key role in the apoptotic pathway, was increased following treatment with 5, 10, 20, or 40
µg/ml 30 nm ceria. Increased levels of oxidative stress related genes (catalase, glutathione S
transferase, HO-1, and thioredoxin reductase) and chromatin condensation were also
observed 94. The effects of nanoceria on BEAS-2B cells were also evaluated in another
study 61. Unlike zinc oxide, nanoceria did not generate oxidant stress or affect cell viability.
A different cell type, human aortic endothelial cells (HAECs), was studied to investigate
systemic inflammation, since this is critical in the development of cardiovascular
pathology 95. HAEC cells were incubated for 4 h with different concentrations of nanoceria
(mean size 44 nm). The exposure produced modest mRNA upregulation of the inflammatory
markers IL-8 and monocyte chemotactic protein-1 that was to some extent concentration
dependent. There was no significant cell loss at any of the concentrations studied 95.
No differences were found in cell morphology of J774A.1 murine macrophages between
nanoceria-treated cells and controls 20. Likewise, there were no significant differences
between apoptosis levels of control and nanoceria-treated cells, and no toxic effects to cells
up to 10 µm nanoceria 20. It was demonstrated that higher toxicity was observed with
nanoceria localized with lysosomes as compared to the cytoplasm 96.
The biological impact of engine emissions using a nanoceria fuel additive compared to that
of a reference fuel was determined using an organotypic culture of lung slices from female
Wistar rats 97. The impact of 10 nm ceria was tested alone. The authors concluded that there
was no impact of nanoceria aerosol on lung tissue viability, glutathione dependent
metabolism, superoxide dismutase activity, or pro-inflammatory reactions. Increased
catalase activity was observed for the 3 concentrations tested, but this did not induce any
loss in cell viability. The authors concluded that the biological effects of the nanoceria fuel
additive are very limited. The observed trend on organotypic culture viability and TNF-α
was viewed as beneficial, while a limited oxidant activity was observed through catalase
induction 97.
Eight experiments were conducted using organotypic cultures of rat lung slices by exposing
the cells to a continuous flow of nanoceria aerosol (mean particle agglomerate diameter 140
nm) over 3 h 4. No effects were found on the viability of the lung tissue slices, glutathione-
dependent metabolism, superoxide dismutase activity, or pro-inflammatory factors 4. It is
unclear just how well or to what extent nanoceria reached key pulmonary effector cells in
these ex vivo organ studies employing lung slices.
Surface charge is an important factor that has been shown to modulate nanoceria toxicity.
Negatively charged nanoceria preferentially entered cancer cells and localized in lysosomes
while positively charged and neutral particles were able to enter cancer as well as normal
cells and mostly localized in the cytoplasm 96. Moreover negatively charged nanoceria have
been shown to induce human lens epithelial cell DNA damage 98, 99. In that work, it was
demonstrated that, in addition to surface charge, time of exposure had greater impact on
DNA damage than particle dose (10 µg/ml nanoceria exposure for 72 vs. 48 h exposure at
100 µg/ml). Other studies also point towards the fact that longer duration exposures may be
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needed to observe nanoceria-induced toxic responses. Dose (3.5 to 23.3 µg/ml) as well as
exposure duration (24 to 72 h) significantly contributed to the toxic effect of nanoceria
towards A549 cells 93. Nanoceria exposure decreased glutathione and alpha-tocopherol
levels and increased malondialdehyde and LDH levels 93. In addition to dose dependence (0
to 10 µg/ml), nanoceria-induced toxicity was time dependent; i.e., 48 h exposure to
nanoceria induced significant apoptosis and autophagy in human peripheral blood
monocytes whereas 24 h exposure resulted in a very mild toxic response 63. Significantly
higher toxicity (decreased mitochondrial activity and DNA content) was reported after 3 to 6
day exposures of MSTO-211H cells or 3T3 fibroblasts to 0 to 30 µg/ml nanoceria 79.
Nanoceria-induced toxicity was comparable to other non-soluble metal oxide nanomaterials
studied (titanium dioxide and zirconium dioxide) but was far less than crocidolite asbestos
(fiber toxicity) or zinc oxide nanoparticles (solubility-driven toxicity). Moreover, there was
cell type specificity in the persistence of the toxic response, since MTSO cell responses
persisted for 6 days while partial recovery of 3T3 cells started after 3 days. Nanoceria was
shown to preferentially kill SCL-1 squamous carcinoma cells through ROS production and
oxidation of proteins at concentrations (150 µM), which were not toxic to dermal
fibroblasts 100. Nanoceria of two sizes (6 and 100 nm) induced size-dependent gene
expression changes and apoptosis, inhibition of G1/S transition, as well as growth inhibition
in murine HT22 hippocampal nerve cells 101.
However, others did not observe any toxic response after nanoceria exposure in BEAS-2B
cells, but rather cytoprotective effects and suppression of exogenously-induced oxidative
stress 61. Nanoceria also had protective effects when cultured cardiomyocytes were exposed
to cigarette smoke extracts 102. Similarly, it was shown that nanoceria protected against
hydrogen peroxide-induced apoptosis in a human breast fibrosarcoma cell line (HT-1080
cells) and had no hemolytic potential towards peripheral red blood cells from healthy human
volunteers 103. Moreover, it was shown that nanoceria-supported gold nanoparticles exerted
higher antioxidant effects than nanoceria particles alone or glutathione in Hep3B and HeLa
cells 104. Some other in vitro studies also demonstrated no toxicity of nanoceria 20, 73, 105.
Differences in production methods, particle shape (sharp vs. round edges), and particle size
are among many differences in the studies showing oxidative vs. antioxidative effects of
nanoceria. We have mentioned above how production method differences lead to differences
in physicochemical characteristics, differential uptake and biological responses. Moreover, it
has already been shown that the ability of nanoceria to agglomerate in water and cell culture
media (RPMI1640) is inversely proportional to their primary particle diameter 106. This
could have important repercussions in the nanoceria uptake pathway and handling by cells,
resulting in different biological outcomes.
In general, nanoceria can be classified as a substance with very low acute toxicity in realistic
exposure levels (albeit in vitro).
Interaction of nanoceria with biological molecules (acellular effects)
Only a few studies have described the interactions of nanoceria with biologically-relevant
molecules 107–111. The ability of nanoceria to cleave the phosphate ester bond in p-
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nitrophenyl phosphate, ATP, and o-phospho-L-tyrosine was demonstrated 109. However,
they observed that nanoceria did not dephosphorylate DNA. The authors concluded that the
ability to perform such reactions is related to the availability of Ce3+ (not Ce4+) sites on the
surface of the particle. They further proposed that DNA may interact with nanoceria in a
similar manner to nucleosomes, by wrapping around the nanoparticle 108. However, contrary
to these findings, others observed that Ce4+ is able to break phosphorous-oxygen bonds (e.g.
in DNA and cAMP) 107, 112. It was demonstrated that nanoceria exhibits ATPase activity (in
acellular conditions as well as inside human vascular endothelial cells), which depends upon
its physicochemical properties (including Ce3+/Ce4+ ratio, morphology, and oxygen
extraction energy) and surface modifications (hexamethylenetetramine used in its
production) 113. These authors suggested that ATPase activity should be considered when
synthesizing nanoceria for therapeutic applications. Moreover, it was demonstrated that
nanoceria catalytic behavior is significantly altered in the presence of phosphate anions 110.
As an abundant amount of inorganic phosphate anions are present in biological systems, it
was postulated that the catalytic behavior of nanoceria may be significantly altered under
physiological conditions. It was demonstrated that nanoceria adsorbs Ca2+ from cell culture
medium and is able to transfer it into cells 114. This resulted in the activation of calcium-
dependent cysteine proteases (calpains) inside the cells 114. Five commercially-available
nanocerias reacted with dopamine 111. Results of spectroscopic and surface characterization
methods suggested nanoceria oxidized dopamine followed by chemisorption of the oxidized
dopamine. This reduced free dopamine, which could have potential neurological
consequences.
These findings demonstrate the possibility of not only changes in nanoceria reactivity but
also changes in biological molecules after nanoceria contact. As the cellular environment is
much more complex inside the organism, the possibility of these, and similar, reactions with
other biological molecules (e.g. with lung lining surfactants, enzymes, etc.) could be
amplified, resulting in unanticipated outcomes. Such interactions could thus significantly
impact biological outcomes and may be the reason for observed discrepancies between in
vitro and in vivo findings 69.
Mechanisms of nanoceria-induced toxicity
The signaling mechanism behind the oxidative response induced by nanoceria was revealed
to be through induction of HO-1 via the p38-Nrf-2 signaling pathway 80. The following
chemical reactions for the oxidative stress and lipid peroxidation produced by nanoceria
were proposed, where A−red is a physiologically relevant reductant like thiol or ascorbate
and LOOH is lipid peroxide 93.
Ce4+ + A−red → Ce3+ + Aox
Ce3+ + O2 → Ce4+ + O2−
O2−+ O2− → O2 + H2O2
H2O2 + Ce3+ → Ce4+ + OH− + OH•
LOOH + Ce3+ → Ce4++LO• + OH−
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Another study with a commercial nanoceria product (7 nm ellipsoidal monocrystallites of
cerianite ((HNO3)0.5(H2O), Rhodia Chemicals, France) and human infant foreskin
fibroblasts (transfected human fibroblast mutants with varying levels of NADPH oxidase
activity), and murine 3T3 fibroblasts, showed that nanoceria can act as a catalyst in
nucleophilic-type reactions, forming the perhydroxyl radical HOO•, the conjugate acid form
of superoxide (O2•) 115.
Based on the available literature, the following mechanisms can be proposed for the
potential toxic effects of nanoceria:
• Oxidative stress-independent mechanisms of nanoceria toxicity relate to formation
of agglomerates in cell culture media, persistence/accumulation of ceria inside
cells/organelles, and damage to the organelles. This accumulation in intracellular
organelles leads to release of proteases (like cathepsins) and results in the
activation of inflammatory and cell death pathways. Indeed, we have recently
demonstrated that nanoceria-induced apoptosis of human peripheral blood
monocytes through oxidative stress-independent mechanisms involving modulation
of autophagy and phagolysosomal accumulation (Figure 2) 63. These mechanisms
are particularly plausible for high aspect ratio nanoceria. Significant contribution of
length (≥ 200 nm) and aspect ratio (≥ 22) were demonstrated in the toxicity
(progressive pro-inflammatory and cytotoxic response) of ceria nanorods and
nanowires towards THP-1 cells 116. The mechanisms behind these responses
included lysosomal damage, NLRP3 inflammasome activation, and IL-1β release.
Nanoceria affected redox-dependent apoptosis through the presence of Ce3+
ions 117. It was further demonstrated that oxygen vacancies do not contribute to this
response. These results further confirm the notion that nanoceria-induced oxidative
stress-independent effects would not benefit from its valance configuration
(Ce3+/Ce4+ redox reactions) and are one plausible explanation for the toxicity of
nanoceria.
• Mechanisms of toxicity related to surface valance state configuration change after
being in contact with biological molecules. A significant reduction of Ce4+ and
appearance of Ce3+ on the surface (i.e. a more redox active state) was proposed to
be the basis of genotoxicity towards human fibroblasts 28. These authors observed a
significant reduction in surface Ce4+ after interaction with organic molecules in
biological media (complemented DMEM). Genotoxicity was observed at 2 to 3
orders of magnitude lower doses than needed to induce cytotoxic effects.
Appearance of more Ce3+ on the surface of nanoceria has already been described as
a cause of nanoceria-induced contact toxicity of bacteria 118. Indeed, it was
reported that increased angiogenesis induction by nanoceria is directly related to
the Ce3+/Ce4+ ratio 119.
• Short term exposure to nanoceria leads to the induction of phase 2 antioxidant
enzymes such as HO-1 and a persistent long-term exposure would result in
defective antioxidant defense leading to reactive oxygen species production and
toxicity.
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• Enzyme mimetic activity of nanoceria, e.g. ATPase-like activity, may contribute to
nanoceria toxicity.
• Either one or a combination of these mechanisms can occur in a given situation and
may result in toxic effects.
What we know
• Nanoceria induces toxicity through similar mechanisms induced by other low
solubility nanomaterials and/or through its unique surface chemical nature. These
mechanisms may or may not mediate nanoceria’s many beneficial effects, which
are described in this issue 12. Mechanisms potentially mediating the beneficial and
adverse effects are also described in this issue 43. However, identification of the
mechanisms contributing to nanoceria toxicity vs. its beneficial effects are not yet
clearly delineated.
Knowledge gaps:
• Existing literature points towards the interaction of nanoceria with biological
molecules. Unfortunately, the exact mechanism of these interactions and their
impact on the observed outcome under in vitro conditions are not known.
• There is a lack of understanding about the so-called “higher sensitivity” of cancer
cells to nanoceria as compared to normal cells. One possible explanation could be
higher metabolic and growth rates of these cells, making them more susceptible to
nanoceria-induced effects.
• Primary cells also demonstrate differential responses to nanoceria. The reasons for
this cell type specificity are not clearly understood. It may be that they lie with
nanoceria characteristics, the biological environment, cell surface receptors of the
cells, or some combination of these.
• It is not known how increased redox activity of nanoceria through increased Ce3+
may lead to toxicity.
• The modifying effects of the protein corona on nanoceria-induced toxicity are not
well understood (as is the case for most nanomaterials).
• In vitro studies cannot accurately represent kinetics and biodistribution in a
complex organism, and thus little is known about distant or secondary effects of
nanoceria exposure.
• It is unknown what mediates distal effects from the site(s) of nanoceria
accumulation, where there is little/no nanoceria.
• Responses of environmentally-relevant nanoceria interacting with all the
modifications taking place in the “natural” environment (e.g. catalytic converters
and diesel exhausts) are not known.
Nanoceria- and cerium-induced human toxicity
No reports were found documenting toxicity to humans from nanoceria or cerium, although
cerium has pharmacological properties that could contribute to adverse effects. Cerium has
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been reported to interfere with calcium function, including an anticoagulant effect, by
inhibition of mitochondrial membrane calcium transport via binding to Ca2+/Mg2+-ATPase,
inhibition of neuronal low voltage-activated (T-type) calcium channels, binding to
calmodulin calcium-binding sites, and substituting for calcium in the regulation of calcium/
CaM-dependent enzymes, contributing to reduced cardiac and skeletal muscle contractility.
It has the ability to inhibit immune responses 120.
Engineering safer by design nanoceria
If we have sufficient information to identify the toxicological risk factors, and if they are
amenable to incorporation into the design of nanoceria, safer by design becomes possible.
The surface properties of nanomaterials are believed to be very important factors influencing
response to nanomaterials. Assessing and understanding the interactions of nanoceria with
environmental and biological systems, as well as identifying means to reduce potential
toxicological outcomes, are pivotal to the sustainability of industries employing nanoceria in
their products. However, while significant research has been directed toward understanding
nano-bio interactions, research toward devising safer engineered nanomaterial (ENM)
formulation concepts that can be readily adopted by the nanotechnology industry is very
sparse 121, 122.
A promising approach in this regard is coating potentially toxic ENMs with a nanothin layer
of biologically and environmentally inert material. The challenge is to generate “core-shell”
ENMs that exhibit the biologically inert surface properties of their shell while preserving
certain important intrinsic functional properties (i.e. optical, magnetic, plasmonic, and
phosphorescence properties) of their core materials.
Recently, a “safer formulation concept” was developed at Harvard and tailored to a family
of ENMs with the highest volume of production 123, namely, flame-generated
nanomaterials. ENMs are coated in-flight with a nanothin layer of amorphous silica. Gas
phase (flame aerosol) processes are the preferred routes for scalable ENM synthesis as they
do not create liquid by-products, offer easier particle collection from gases than liquids,
usually include fewer process steps, and result in high purity materials with unique
morphologies, including the synthesis of metastable phases 124. However, it is worth
pointing out that wet synthesis methods result to more uniform sizes of nanomaterials
compared to flame synthesis of nanomaterials. Flame-made nanoparticles typically yield
lognormal particle size distributions with a geometric standard deviation of 1.45 125.
Amorphous silica has a reduced toxicological footprint and is often used as a negative
control material in in vitro ENM screening assays 79. Nanothin silica therefore has potential
to shield otherwise potentially toxic core materials from interactions with environmental and
biological systems. It was demonstrated in many studies that coating nanoparticles with
silica preserves certain important intrinsic functional properties (i.e. optical 126,
magnetic 127, 128, plasmonic 129, and phosphorescence 130) of the core materials.
The applied silica-coating process in flames has major advantages over wet-methods, such
as sol-gel 131, and reverse micro-emulsion 132, which are frequently applied to the synthesis
of silica-coated nanoparticles by industry. These low yield, multi-step, wet synthesis
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methods often produce porous silica coatings 133, which cannot sufficiently protect
surrounding media from any potential toxic implications of the core materials. A flame-
based silica-coating process has recently been explored as a means of high yield scalable
nanomanufacturing of silica-coated ENMs, such as titanium oxide, iron oxide, zinc oxide,
ceria, and silver 69, 134.
Silica encapsulation strategy for nanoceria
Figures 3 (a) and (b) illustrate the proposed approach and underlying theory to the one-step
nanoparticle synthesis, and in-flight silica-encapsulation, respectively. In brief, core
nanoparticles are formed in the gas phase by flame spray pyrolysis of organometallic
compounds dissolved in high enthalpy solvents 135. The freshly formed core nanoparticles
pass through the silica coating region, where they are encapsulated with a nanothin (1- 5
nm) amorphous silica layer by the swirl-injection of hexamethyldisiloxane (HMDSO)
vapor-laden N2.
Ceria and silica-coated nanoceria synthesis
Uncoated and silica-coated nanoceria particles were synthesized by flame spray pyrolysis of
Ce3+ ethylhexanoate (0.05 M) dissolved in xylene and cerium3+ ethylhexanoate (0.04 M)
dissolved in xylene: ethylhexanoate (3:1), respectively, as described in detail 69, 134.
Ex situ characterization of generated ENMs
Figure 4 shows TEM and SEM images of nanoceria and SiO2-coated nanoceria samples
collected in situ (panels c-f). The images illustrate the fractal structure of the agglomerates
formed by the flame synthesis method. In the case of silica-coated nanoceria, a smooth and
relatively homogenous 2 to 4 nm silica coating layer is visible around the core ceria particles
at higher magnification (Figure 4 (g)). The hermetic silica encapsulation of nanoceria was
also evaluated using X-ray photoelectron spectroscopy (Figure 4 (b)). As shown in this
figure, the Ce 3d electron transition almost entirely disappears in the silica-coated nanoceria
survey spectra. Small Ce 3d peaks that remain visible in the silica-coated nanoceria spectra
can be attributed to a bulk Ce signal 136. This is in agreement with previous data showing
coating thicknesses between 2 to 3 nm resulted in close to hermetic encapsulation of the core
nanoceria 134. Figure 4 (a) shows X-ray diffraction (XRD) patterns for nanoceria and silica-
coated nanoceria. The location of the peaks is identical for both materials, indicating that the
coating had minimal effect on core composition and crystal structure. XRD-determined
crystal size of uncoated ceria (17.3 nm) was slightly smaller than the silica-coated ceria (21
nm). The SSA of uncoated ceria was 61 m2/g and that of silica-coated ceria was 50 m2/g,
corresponding to equivalent diameters of 12.8 and 19.2 nm, respectively. Differences
between nanoceria and silica-coated BET equivalent diameter are more pronounced than
crystal sizes due to silica encapsulation, which is not accounted for when measuring the
crystal size.
In vivo toxicological characterization of ENMs prepared by the safer by design approach
An animal model was used to assess the effect of the silica coating on the toxicological
profile of inhaled nanoceria. In brief, male Sprague-Dawley rats were exposed to 2.7 mg/m3
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of silica-coated nanoceria, uncoated nanoceria, or a particle-free environment (controls) (2
h/day, 4 days). Twenty-four h post exposure the animals were sacrificed.
Alveolar phagocytes and biomarkers of injury and inflammation were obtained by BAL.
Complete pathophysiological analysis was performed. Inflammatory and cytotoxicity
biomarkers, including cell counts of PMNs and AMs, LDH activity, and albumin content,
were measured in the BALF.
Figure 5 summarizes inflammatory and cytotoxicity biomarkers in the BALF of the animals
sacrificed 24 h post exposure. While exposure to uncoated nanoceria induced considerable
PMN infiltration compared to the control group, an indicator for inflammation, PMN levels
for the silica-coated scenario were similar to the particle-free control group levels (Figure 5
(b)). Similarly, LDH release from the uncoated nanoceria-exposed group was significantly
higher than the particle-free exposed control group, as shown on Figure 5 (d). In contrast,
LDH release in the silica-coated nanoceria-exposed group was nearly identical to that of the
particle–free exposed control group, clear evidence that silica coating results in reduced
toxicity (Figure 5 (d)). Furthermore, neither nanoceria nor silica-coated nanoceria exposure
appeared to cause air/capillary damage, as shown by similar albumin levels for silica-coated,
uncoated nanoceria, and the particle-free control animal group (Figure 5 (c)). This is
compelling evidence that the silica encapsulation significantly reduced particle toxicity.
Other than a demonstration that titanium doping of nanoceria reduced its superoxide
dismutase activity 137, there do not appear to be any reports of the biological effects of
nanoceria doping.
Knowledge gap
• The stability of the silica coating in vivo and potential risk from chronic silica-
coated nanoceria exposure needs to be assessed.
Safer by design conclusions
The versatile and scalable process outlined here enables the one step, inflight, hermetic
encapsulation of nanoceria with a nanothin silica layer. Preliminary toxicological evidence
demonstrates the ability of the proposed concept to reduce the toxicological profile of
nanoceria, while maintaining the functional properties of the core materials. The described
concept bears great promise for large-scale industrial application as a means of effectively
inhibiting nanoparticle toxicity.
Research recommendations
1. Address why some studies report toxic effects of nanoceria while others report that
nanoceria is of low toxicity and exhibits antioxidant properties. Are these
differences due to:
a) valance state or synthesis temperature of the nanoceria;
b) the physicochemical properties of the sample tested;
c) the dose, exposure route, or experimental model used?
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2. Evaluate the initial site(s) of deposition, clearance, translocation, elimination, and
biological effect of nanoceria given by various exposure routes (IV, IP, oral,
inhalation). How would various physicochemical properties affect such
biokinetics?
3. Determine the effects of interaction of nanoceria with biological fluids (blood, lung
lining fluid, etc.) on agglomeration, surface reactivity, and bioactivity.
4. Compare the effects of short-term/high-dose exposure to long-term/low-dose
exposure of the same total burden. Determine no effect levels.
5. Characterize the effects of co-exposure (diesel plus cerium fuel additive) on
pulmonary and cardiovascular response.
6. Develop predictive in vitro tests that:
a) use doses relevant to in vivo exposure;
b) evaluate mechanisms other than oxidant stress;
c) evaluate genotoxicity and induction of cell proliferation/transformation.
7. Address why some studies report toxic effects of nanoceria while others report that
nanoceria is of low toxicity and exhibits antioxidant properties. Are these
differences due to:
d) valance state or synthesis temperature of the nanoceria;
e) the physicochemical properties of the sample tested;
f) the dose, exposure route, or experimental model used?
8. Evaluate the initial site(s) of deposition, clearance, translocation, elimination, and
biological effect of nanoceria given by various exposure routes (IV, IP, oral,
inhalation). How would various physicochemical properties affect such
biokinetics?
9. Evaluate the initial site(s) of deposition, clearance, translocation, elimination, and
biological effect of nanoceria given by various exposure routes (IV, IP, oral,
inhalation). How would various physicochemical properties affect such
biokinetics?
10. Determine the effects of interaction of nanoceria with biological fluids (blood, lung
lining fluid, etc.) on agglomeration, surface reactivity, and bioactivity.
11. Compare the effects of short-term/high-dose exposure to long-term/low-dose
exposure of the same total burden. Determine no effect levels.
12. Characterize the effects of co-exposure (diesel plus cerium fuel additive) on
pulmonary and cardiovascular response.
13. Develop predictive in vitro tests that:
d) use doses relevant to in vivo exposure;
e) evaluate mechanisms other than oxidant stress;
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f) evaluate genotoxicity and induction of cell proliferation/transformation.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Abbreviations
ALT alanine aminotransferase
AM alveolar macrophages
BAL bronchoalveolar lavage
BBB blood-brain barrier
BEAS-2B cells human bronchial epithelial cells
BET Brunauer, Emmett and Teller surface area determination
EDTA ethylenediaminetetraacetic acid
EELS electron energy loss spectrometry
ENM engineered nanomaterial, FTIR, Fourier transform infrared spectroscopy
GI gastrointestinal
GPx glutathione peroxidase
GR glutathione reductase
GSH/GSSG reduced/oxidized glutathione ratio
H & E hematoxylin and eosin stain
HAEC human aortic endothelial cells
HNE protein-bound 4-hydroxy 2-transnonenal
HO-1 heme oxygenase-1
Hsp70 heat shock protein 70
iNOS inducible nitric oxide synthase
LDH lactate dehydrogenase
LC-3 AB antibody to light Chain 3, an autophagy marker
MCP-1 monocyte chemoattractant protein-1, an inflammatory marker
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MPS mononuclear phagocyte system, 3NT, 3-nitrotyrosine
OECD TG 412 Organisation for Economic Co-operation and Development, Guideline
for the Testing of Chemicals: Subacute Inhalation Toxicity: 28-Day
Study
OECD TG 453 Test Guideline 453: Combined Chronic Toxicity\Carcinogenicity
Studies
ROS reactive oxygen species
SEM scanning electron microscope
SOD superoxide dismutase
SSA specific surface area
TEM transmission electron microscopy
XRD X-ray diffraction
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Figure 1.
The percentage of the injected dose in the liver and spleen after intravenous nanoceria
administration of various sizes, shapes, doses, and surface-coatings. ● = Five nm,
polyhedral, citrate-coated, 85 mg/kg to rats 22. ■ = Fifteen nm, polyhedral, citrate-coated,
70 mg/kg to rats 22. ▲ = Thirty nm, platelets, coated with an unknown carboxylate, 50, 250
and 750 mg/kg to rats 13. ▼ = Thirty nm, cubic, citrate coated, 85 mg/kg to rats. ○ = Three
to 5 nm, 10 to 50 nm agglomerates, fluorescent-tagged, 0.5 mg/kg weekly for 5 weeks to
mice, terminated 1 week later 19. ◊ = 5.6 nm, 3-aminopropylsilyl-anchored N-succinimidyl
Yokel et al. Page 37
Environ Sci Nano. Author manuscript; available in PMC 2015 October 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
4-[18F]fluorobenzoate coated, 4.8 MBq to rats 23. □ = 2.9 nm, citrate-EDTA coated, 20
mg/kg to mice 24. Line is best polynomial (quadratic) fit. Cerium was quantified by ICP-
OES or ICP-MS 13, ICP-MS 18, 19, 22, 24, or positron emission tomography 23.
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Figure 2.
Mechanism of nanoceria-induced toxicity in human peripheral blood monocytes. Nanoceria
induces programmed cell death (apoptosis) through a mitochondrial damage pathway
(involving activation and mitochondrial localization of Bax, decreased mitochondrial
membrane potential (ΔΨm), and overexpression of apoptosis inducing factor (AIF)).
Nanoceria-induced autophagy was characterized by increased LC3B-stained autophagic
vesicles, monodansylcadaverine-stained autophagosomes/autolysosomes and increased
lysosomal production of LC3b+ phagolysosomes. Inhibition of p53 using its
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pharmacological inhibitor (pifithrin-α) increased the autophagy. Inhibition of autophagy
through wortmannin decreased the cytotoxicity, indicating a pro-death role of autophagy.
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Figure 3. ENM synthesis and silica coating fundamentals
(a) A schematic of the coating reactor highlighting the most important elements. Core ENMs
are formed through the combustion, by a flame spray pyrolysis (FSP) burner of
organometallic compounds dissolved in high enthalpy solvents. The HMDSO vapor is
injected into the particulate flow in an in-line silica-coating reactor. (b) The mechanism of
the coating and the possible results. The high temperatures obtained in the core particle
synthesis provide the necessary energy for the HMDSO conversion to silica vapor. Under
optimal silica vapor supersaturation conditions, the silica vapor nucleates heterogeneously
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onto the core ENM surface, thereby forming a desired silica coating layer of a controlled
thickness. Reprinted, with permission, from 69.
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Figure 4. Physicochemical ENM characterization
XRD (a) and XPS (b) spectra of nanoceria (black) and silica-coated nanoceria (red) (dXRD:
crystal size measured by X-ray diffraction). In situ SEM (c, d) and TEM (e, f) images of
nanoceria and silica-coated nanoceria. Higher resolution TEM image of silica-coated
nanoceria (ex situ); 2 to 4 nm silica coating appears as lighter contrast around darker contrast
core nanoceria particles (g). Reprinted, with permission, from 69.
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Figure 5. In vivo toxicity
Alveolar macrophages (AM) (a), polymorphonuclear neutrophils (PMNs) (b), albumin (c),
and lactate dehydrogenase (LDH) (d) levels in bronchoalveolar lavage (BAL) of rats
sacrificed 1 day post-exposure. Error bars represent standard error, * represents p value <
0.05, Transmission electron microscopy (TEM) images of AM recovered from the BAL of
rats instilled with nanoceria (e) and silica-coated nanoceria particles (f). Reprinted, with
permission, from 69.
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